Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is funded by PER®.

Targeting NTRK Fusions Across Tumor Types

Release Date: July 29, 2021
Expiration Date: July 29, 2022

Activity Overview

This continuing medical education (CME) activity provides expert insight regarding the role of members of the neurotrophic tyrosine receptor kinase (NTRK) gene family in the normal neural physiology and in fusion genes that drive tumor development. This program reviews data from clinical trials regarding the use of tropomyosin-related kinase (TRK) inhibitors to treat patients who have NTRK fusion-positive cancer. Mechanisms of acquired resistance to TRK inhibitor therapy are discussed, as well as on-target adverse events.

Acknowledgement of Commercial Support

This activity is funded by PER®.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:
  • Describe the physiologic functions of TRK proteins in healthy cells

  • Explain the rationale for targeting NTRK fusions in the treatment of cancer

  • Assess key data from clinical trials evaluating therapeutic agents targeting NTRK fusions for the treatment of cancer

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.


Alexander Drilon, MD
Alexander Drilon, MD
Chief, Early Drug Development Service
Associate Attending, Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: Grant/Research Support: Pfizer, Exelixis, GlaxoSmithKlein, Teva, Taiho, PharmaMar , Foundation Medicine. Consultant: Ignyta/Genentech/Roche, Loxo/Bayer/Lilly, Takeda/Ariad/Millenium, TP Therapeutics, AstraZeneca, Pfizer, Blueprint Medicines, Helsinn, Beigene, BergenBio, Hengrui Therapeutics, Exelixis, Tyra Biosciences, Verastem, MORE Health, Abbvie, 14ner/Elevation Oncology, Remedica Ltd., ArcherDX, Monopteros, Novartis, EMD Serono, Melendi, Liberum, Repare RX. Other Support: Royalties- Wolters Kluwer, Food/Beverage- Merck, Puma, Merus, Other- Boehringer Ingelheim, CMEHonoraria- Targeted Oncology, Axis, WebMD.

This activity was written by PER® editorial staff under faculty guidance and review. The Q&A portion of the activity was transcribed from a recorded interview with the faculty and edited by faculty and PER® editorial staff for clarity.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By